RxDoctor Payments Data

Jose Caceres, MD

Pulmonary Disease · Little Rock, ARNPI 1194087965

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $5,280 of the $6,025 with a category attached, or 87.6%. 8 manufacturers reported payments, led by Steris Corporation at 41.1% of the total. Reporting peaked in 2024 at $2,550 and has fallen 94.5% since, to $141 in 2025.

$6,025in general payments, 2019–2025

Across 33 payments — averaging $182.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Steris Corporation$2K
  • Intuitive Surgical$2K
  • Pinnacle Biologics, Inc$1K
  • Veran Medical Technologies, Inc.$149
  • Olympus America Inc.$138
  • Pulmonx Corporation$62
  • plus $28 from 2 others

What the payments were for

  • Travel & lodging$5,28088%
  • Food & beverage$72912%
  • Education$150%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,025 in reported general payments places this provider in the 70th percentile of 102 pulmonary disease providers in Arkansas.

See all pulmonary disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$79,951
Medicare patients
221
Services billed
555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Spiriva HandihalerTiotropium Bromide29$16,497
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,507
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,500
SymbicortBudesonide/Formoterol Fumarate31$10,182
Incruse ElliptaUmeclidinium Bromide29$10,022
Spiriva RespimatTiotropium Bromide18$9,103
Acetylcysteine19$6,095
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,370
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,267
Albuterol Sulfate HfaAlbuterol Sulfate80$2,022
Prednisone22$115
Omeprazole13$50
Montelukast Sodium12$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Symbicort$15$22,68251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 102 pulmonary disease providers in Arkansas.

Other pulmonary disease in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →